Anifrolumab (Saphnelo) Gets Green Light for Approval in EU

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended marketing authorization for anifrolumab (Saphnelo) as an add-on treatment for adults with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite standard therapy, according to an announcement on Dec. 16.

Anifrolumab, a monoclonal antibody that binds to subunit 1 of the type I interferon receptor and thereby blocks the biologic activity of type I interferons, was approved by the US Food and Drug Administration in July 2021.

The recommendation for anifrolumab is based on its ability to elicit a clinical response on the British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) at week 52, which is defined as improvement in all organ domains with moderate or severe SLE activity at baseline.

The manufacturer AstraZeneca said the biologic drug will be available as a 300 mg concentrate for solution for infusion.

The most common adverse reactions are upper respiratory tract infection, bronchitis, infusion-related reaction, and herpes zoster. The most common serious adverse reaction was herpes zoster.

For more news, follow Medscape on Facebook, Twitter, Instagram, and YouTube.

Note: This article have been indexed to our site. We do not claim legitimacy, ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
How Far Should the Menthol Ban Go? thumbnail

How Far Should the Menthol Ban Go?

On April 28, the FDA announced regulations to prohibit menthol as a characterizing flavor in cigarettes and all characterizing flavors (other than tobacco) in cigars. The agency said the proposals "have the potential to significantly reduce disease and death from combusted tobacco product use, the leading cause of preventable death in the U.S., by reducing…
Read More
Cerner previews its new products and plans for HIMSS22 thumbnail

Cerner previews its new products and plans for HIMSS22

While electronic health record giant Cerner has been in the spotlight of late because of its pending acquisition by Oracle, that is not what the health IT company will be highlighting in the exhibit hall of the upcoming HIMSS Global Health Conference & Exhibition in Orlando, March 14-18. Interoperability, organ donation technologies, public health reporting…
Read More
Thriving with a rare disorder thumbnail

Thriving with a rare disorder

At first glance, nobody can tell all the struggles I’ve endured in an era that is all about image. While genetic disorders affect individuals in rare cases, intellectual disabilities, depression and anxiety occur most frequently in men and women. These conditions are only some of the health issues I regularly face. In retrospect, I shouldn’t
Read More
Index Of News
Total
0
Share